Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Descending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
25021-0788-74 25021-0788 Palonosetron Hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 15, 2018 In Use
25021-0784-10 25021-0784 Fosaprepitant Dimeglumine Fosaprepitant 150.0 mg/5mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Dec. 15, 2019 In Use
25021-0783-05 25021-0783 palonosetron hydrochloride palonosetron hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous June 15, 2018 In Use
25021-0782-20 25021-0782 ondansetron hydrochloride Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 30, 2012 Nov. 30, 2021 No Longer Used
25021-0781-04 25021-0781 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 1, 2010 Aug. 1, 2019 No Longer Used
25021-0779-04 25021-0779 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 1, 2010 Oct. 15, 2012 No Longer Used
25021-0779-01 25021-0779 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 1, 2010 June 1, 2019 No Longer Used
25021-0778-66 25021-0778 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous May 31, 2013 Jan. 31, 2017 No Longer Used
25021-0778-01 25021-0778 Granisetron Hydrochloride Granisetron Hydrochloride 0.1 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Dec. 1, 2010 Feb. 1, 2017 No Longer Used
25021-0777-02 25021-0777 ondansetron hydrochloride Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Aug. 30, 2012 In Use
25021-0467-05 25021-0467 Octreotide acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 15, 2023 In Use
25021-0466-05 25021-0466 Octreotide acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 15, 2023 In Use
25021-0465-01 25021-0465 Octreotide acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous April 15, 2023 In Use
25021-0464-01 25021-0464 Octreotide acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 15, 2023 In Use
25021-0463-01 25021-0463 Octreotide acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous June 15, 2023 In Use
25021-0462-74 25021-0462 fulvestrant fulvestrant 50.0 mg/mL Hormonal Therapy Estrogen Receptor Antagonist Intramuscular Aug. 1, 2019 April 30, 2023 In Use
25021-0455-05 25021-0455 Octreotide Acetate Octreotide Acetate 1000.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Feb. 29, 2020 In Use
25021-0454-05 25021-0454 Octreotide Acetate Octreotide Acetate 200.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 March 31, 2021 In Use
25021-0453-01 25021-0453 Octreotide Acetate Octreotide Acetate 500.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Feb. 28, 2023 In Use
25021-0452-01 25021-0452 Octreotide Acetate Octreotide Acetate 100.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 Jan. 31, 2023 In Use
25021-0451-01 25021-0451 Octreotide Acetate Octreotide Acetate 50.0 ug/mL Hormonal Therapy Somatostatin Analog Intravenous, Subcutaneous Dec. 15, 2013 In Use
25021-0258-61 25021-0258 Melphalan Hydrochloride Melphalan Hydrochloride 50.0 mg/10ml Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous April 1, 2024 In Use
25021-0255-50 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-17 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0255-05 25021-0255 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb. 1, 2024 In Use
25021-0254-16 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
25021-0254-08 25021-0254 Docetaxel Anhydrous Docetaxel 10.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Aug. 1, 2023 In Use
25021-0253-51 25021-0253 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2023 In Use
25021-0253-50 25021-0253 Cisplatin Cisplatin 1.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 1, 2023 In Use
25021-0252-51 25021-0252 Mitomycin Mitomycin 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0251-50 25021-0251 Mitomycin Mitomycin 20.0 mg/40mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0250-20 25021-0250 Mitomycin Mitomycin 5.0 mg/10mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous June 15, 2023 In Use
25021-0249-51 25021-0249 Cyclophosphamide Cyclophosphamide 2.0 g/100mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0248-51 25021-0248 Cyclophosphamide Cyclophosphamide 1.0 g/50mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Jan. 15, 2024 In Use
25021-0246-02 25021-0246 Thiotepa Thiotepa 15.0 mg/1.5mL Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical June 15, 2018 In Use
25021-0245-04 25021-0245 Docetaxel Anhydrous Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 15, 2017 In Use
25021-0245-01 25021-0245 Docetaxel Anhydrous Docetaxel 20.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Sept. 15, 2017 In Use
25021-0244-10 25021-0244 BORTEZOMIB BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 1, 2022 In Use
25021-0242-02 25021-0242 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Oct. 15, 2016 In Use
25021-0241-10 25021-0241 Busulfan Busulfan 6.0 mg/mL Chemotherapy Alkylating Agent Alkylsulfonate Intravenous May 15, 2017 In Use
25021-0239-52 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Aug. 31, 2020 No Longer Used
25021-0239-26 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Feb. 28, 2021 No Longer Used
25021-0239-05 25021-0239 gemcitabine Gemcitabine 38.0 mg/mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Jan. 15, 2019 Sept. 30, 2020 No Longer Used
25021-0237-06 25021-0237 Fludarabine phosphate Fludarabine phosphate 25.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Dec. 15, 2014 June 30, 2019 In Use
25021-0236-04 25021-0236 Topotecan Topotecan 1.0 mg/mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Dec. 15, 2014 Jan. 31, 2021 No Longer Used
25021-0235-51 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 15, 2022 In Use
25021-0235-50 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
25021-0234-10 25021-0234 Gemcitabine Hydrochloride gemcitabine 200.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
25021-0233-20 25021-0233 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2014 In Use
25021-0233-10 25021-0233 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous Sept. 15, 2014 In Use

Found 10,000 results in 10 milliseconds — Export these results